Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Watson Files FDA Applications for Generic Mucinex(R)

By Pharmaceutical Processing | April 22, 2009

Watson Pharmaceuticals,Inc., a specialty pharmaceutical company, has filed two Abbreviated New Drug Applications (ANDAs) with the FDA seeking approval to market its guaifenesinextended-release 600mg and 1200mg tablets and its dextromethorphanHBr/guaifenesin extended-release 30mg/600mg and 60mg/1200mg tablets prior tothe expiration of patents owned by Reckitt Benckiser Inc. Watson’sguaifenesin and dextromethorphan HBr/guaifenesin extended-release tabletproducts are the generic versions of Reckitt Benckiser Inc.’s Mucinex(R) andMucinex(R) DM products which are indicated to help loosen phlegm (mucus) andthin bronchial secretions to rid the bronchial passageways of bothersome mucusand make coughs more productive. Reckitt Benckiser filed suit against Watson on April 20, 2009 in the U.S.District Court for the Southern District of New York seeking to prevent Watsonfrom commercializing its products prior to expiration of U.S. patent numbers6,372,252 and 6,955,821. Reckitt Benckiser’s suit was filed under theprovisions of the Hatch Waxman Act, resulting in a stay of final FDA approvalof Watson’s ANDAs for up to 30 months or until final resolution of the matterbefore the court, whichever occurs sooner. Based on available information,Watson believes it may be the first applicant to file an ANDA for a genericversion of Mucinex DM(R) and, should its product be approved, may be entitledto 180 days of generic market exclusivity. For the twelve-months ended December 31, 2008, Mucinex(R) and Mucinex(R)DM products had total U.S. sales of approximately $106 million and $85 millionrespectively, according to IMS Health data.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE